• 1
    Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998; 19: 327.
  • 2
    Julander I, Svanbom M. Prediction of staphylococcal etiology among patients with septicemia with or without endocarditis by multivariate statistical methods. Scand J Infect Dis 1985; 17: 3746.
  • 3
    Kuikka A, Valtonen VV. Improved outcome of Staphylococcus aureus bacteremia. Infect Dis Clin Pract 1994; 3: 2827.
  • 4
    Watanakunakorn C, Chan SJ, Demarco DG, Palmer JA. Staphylococcus aureus bacteremia: significance of hyperbilirubinemia. Scand J Infect Dis 1987; 19: 195203.
  • 5
    Soriano A, Martinez JA, Mensa J et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30: 36873.
  • 6
    Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000; 31: 11704.
  • 7
    Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 7829.
  • 8
    Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 2532.
  • 9
    Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 206672.
  • 10
    Chang FY, Peacock JE Jr , Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 3339.
  • 11
    Jensen AG. Importance of focus identification in the treatment of Staphylococcus aureus bacteraemia. J Hosp Infect 2002; 52: 2936.
  • 12
    Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 52032.
  • 13
    Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987; 9: 891907.
  • 14
    Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 2000; 28: 1326.
  • 15
    Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16: 56773.
  • 16
    Fatkenheuer G, Preuss M, Salzberger B et al. Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2004; 23: 15762.
  • 17
    Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002; 16: 41335.
  • 18
    Tan JS, File TM Jr. Management of staphylococcal and streptococcal infections. Clin Podiatr Med Surg 1996; 13: 793816.
  • 19
    Van der Auwera P, Klastersky J. In vitro study of the combination of rifampicin with oxacillin against Staphylococcus aureus. Rev Infect Dis 1983; 5 (Suppl.): S50914.
  • 20
    Van der Auwera P, Meunier-Carpentier F, Klastersky J. Clinical study of combination therapy with oxacillin and rifampicin for staphylococcal infections. Rev Infect Dis 1983; 5 (Suppl.): S51522.
  • 21
    Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpentier F, Legrand JC. Double-blind, placebo-controlled study of oxacillin combined with rifampicin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985; 28: 46772.
  • 22
    Craig WA. Rifampicin and related drugs. In: GorbachSL, BartlettJG, BlacklowNR, eds. Infectious Diseases. Philadelphia, PA: Lippincott Williams & Wilkins, 2004; 27780.
  • 23
    Calfee DP. Rifamycins. In: MandellGL, BennettJE, DolinR, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone, 2005; 37487.
  • 24
    Kapusnik JE, Parenti F, Sande MA. The use of rifampicin in staphylococcal infections – a review. J Antimicrob Chemother 1984; 13 (Suppl.): 616.
  • 25
    Fu KP, Lafredo SC, Foleno B et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992; 36: 8606.
  • 26
    Rohner P, Herter C, Auckenthaler R, Pechere JC, Waldvogel FA, Lew DP. Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother 1989; 33: 203741.
  • 27
    Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989; 2: 10713.
  • 28
    Heldman AW, Hartert TV, Ray SC et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101: 6876.
  • 29
    Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampicin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 153741.
  • 30
    Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 23540.
  • 31
    Schrenzel J, Harbarth S, Schockmel G et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004; 39: 128592.
  • 32
    Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984; 144: 5415.
  • 33
    Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 124972.
  • 34
    Rahal JJ Jr, Chan YK, Johnson G. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am J Med 1986; 81: 4352.
  • 35
    Moreillon P, Que YA. Infective endocarditis. Lancet 2004; 363: 13949.
  • 36
    McCabe WR, Jackson GG. Gram negative bacteraemia 1. Etiology and ecology. Arch Intern Med 1962; 110: 84755.
  • 37
    Li JS, Sexton DJ, Mick N et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 6338.
  • 38
    Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 297684.
  • 39
    Lyytikäinen O, Ruotsalainen E, Järvinen A, Valtonen V, Ruutu P. Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995–2001. Eur J Clin Microbiol Infect Dis 2005; 24: 399404.
  • 40
    Kim SH, Park WB, Lee KD et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003; 37: 7949.
  • 41
    Benfield T, Espersen F, Frimodt-Moller N et al. Trends in incidence and mortality among 23962 adult cases of Staphylococcus aureus bacteremia from 1971 through 2000. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30–November 2, 2004: L-357 (abstract).
  • 42
    Fowler VG Jr, Sanders LL, Sexton DJ et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27: 47886.
  • 43
    Moreillon P, Que YA, Glauser MP. Staphylococcus aureus (including staphylococcal toxic shock). In: MandellGL, BennettJE, DolinR, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone, 2005; 232151.
  • 44
    Chang FY, MacDonald BB, Peacock JE Jr et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 32232.
  • 45
    Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampicin therapy. South Med J 1986; 79: 94751.